Daily BriefsEquity Bottom-Up

Daily Brief Equity Bottom-Up: Grab(GRAB.US) 4Q22 Preview: Tailwinds from Share Gain and Rebound in Mobility and more

In today’s briefing:

  • Grab(GRAB.US) 4Q22 Preview: Tailwinds from Share Gain and Rebound in Mobility
  • Q&M Dental Group (QNM SP): Core HealthCare Business Exhibits Secular Uptrend; Expansion to Continue
  • Era of the Value Stocks
  • Softbank Corp (Buy) – Q3 22 Results Reaction: Modest Mobile Improvement, on Track to Meet Targets
  • Jeju Air: A Big Beneficiary of Travel Resurgence in Asia + A Likely Inclusion in KOSPI 200 in 2023
  • SK Biopharmaceuticals (326030 KS): Global Expansion to Accelerate Growth Trajectory of Epilepsy Drug
  • Intel Corp: Launch Of 13th Generation Lineup & Other Drivers
  • Picton Property Income – Growing income and portfolio outperformance
  • Comcast Corporation: Major Drivers
  • Amazon: Recent Quarter Is A Reminder That Red Flags Should Not Be Ignored

Grab(GRAB.US) 4Q22 Preview: Tailwinds from Share Gain and Rebound in Mobility

By Shawn Yang

  • In C4Q22, We expect Grab to report total revenue 2% higher than cons., and non-IFRS net loss narrower than cons.. 
  • With competitors cutting back on heavy incentives, Grab has gained share under easing competitive environment in food delivery market in 2022. We expect this trend to sustain in 2023.
  • Mobility is expected to benefit from rebound of tourism and generate stable margin. Pullbacks from off-platform financial services continue to support improvement. Maintain BUY and raise TP to US$ 4.0.

Q&M Dental Group (QNM SP): Core HealthCare Business Exhibits Secular Uptrend; Expansion to Continue

By Tina Banerjee

  • Q & M Dental Group (Singapore) (QNM SP) is the largest listed pure dental play in Southeast Asia. For the 9M2022, core healthcare revenue increased 3% to S$125.9M.
  • Comparison of the numbers over five quarters to mitigate any impact of changes in the economic and business environment shows core healthcare revenue exhibits a secular uptrend.
  • During 9M2022, Q&M added seven and four dental clinics in Singapore and Malaysia, respectively, bringing the company’s total number of clinics to 106 in Singapore and 45 in Malaysia.

Era of the Value Stocks

By Nurture Capital Advisory

  • Era of the value stocks! Inflation feeds interest rates, raises cost of capital and risks equity multiples. Headwinds to earnings growth – risks sustenance of pricey valuations.  
  • Key risks: Stocks face material headwinds on cost pressure, competition, valuations 
  • Stocks covered: Crompton Greaves, Stove Kraft, Lemon Tree, Jubilant Ingrevia

Softbank Corp (Buy) – Q3 22 Results Reaction: Modest Mobile Improvement, on Track to Meet Targets

By Kirk Boodry

  • Consumer mobile revenue fell 7% but that partly reflects how sales were reported a year ago. Reported ARPU was down 5% whilst price cut erosion narrowed
  • Operating income YTD is 94% of full-year targets leaving room for Softbank to achieve its goal even with increased investment spending
  • This was a relatively uneventful quarter and we remain at Buy

Jeju Air: A Big Beneficiary of Travel Resurgence in Asia + A Likely Inclusion in KOSPI 200 in 2023

By Douglas Kim

  • We believe that Jeju Air is in a sweet spot right now. Jeju Air is one of the major beneficiaries of the travel resurgence in Asia.
  • Jeju Air is a potential inclusion candidate in the KOSPI 200 index in 2023. There are 42 companies in KOSPI 200 which have lower market cap than Jeju Air. 
  • Outbound travel from Korea recovered strongly with 6.6 million outbound tourists from South Korea in 2022, up 436% YoY. However, this is still 77% lower than the figure in 2019. 

SK Biopharmaceuticals (326030 KS): Global Expansion to Accelerate Growth Trajectory of Epilepsy Drug

By Tina Banerjee

  • SK Biopharmaceuticals Co Ltd (326030 KS) is reporting continued stellar performance of its flagship drug Xcopri (cenobamate) in the U.S., with 9M2022 sales rising 137% YoY to KRW119B.
  • Since its launch, Xcopri maintained strong momentum in US in terms of prescription volume. Xcopri reported 1.8x higher launching TRx than recently launched competitive anti-epileptic drugs (AEDs).
  • The company plans to launch cenobamate in the Middle East and Africa this year, following launches in the U.S., China, Japan, and major countries in Europe.

Intel Corp: Launch Of 13th Generation Lineup & Other Drivers

By Baptista Research

  • Intel delivered a weak result, failing to meet Wall Street expectations in terms of revenues as well as earnings given the persisting macroeconomic headwinds in the semiconductor industry.
  • Intel continues to integrate AXG into CCG and DCAI to deliver a more effective go-to-market capability, accelerating the scale of these businesses while further cutting costs.
  • The management believes their first EUV-deploying modes, Intel 4 and 3, will significantly improve transistor performance per watt and density.

Picton Property Income – Growing income and portfolio outperformance

By Edison Investment Research

Picton Property Income’s (PCTN’s) Q323 report shows asset management and leasing activity continuing to grow rental income. This provided a partial offset to strong market-wide pressure on property valuations in response to higher interest rates, while moderate gearing mitigated the impact on NAV. Although the NAV total return was a negative 11.7%, PCTN appears to have delivered strong outperformance relative to MSCI indices and those immediate peers that have so far reported.


Comcast Corporation: Major Drivers

By Baptista Research

  • Comcast achieved a strong result that surpassed Wall Street expectations in terms of revenues as well as earnings.
  • The company is slowly growing its ARPU as it is working towards building its customer relationships by steadily introducing new capabilities, services, and benefits.
  • In 2023, ARPU growth should continue to be the main factor influencing their residential broadband revenue growth.

Amazon: Recent Quarter Is A Reminder That Red Flags Should Not Be Ignored

By Vladimir Dimitrov, CFA

  • Amazon’s share price has fallen 25% since April of last year, sparking a fear of missing out.
  • The pressure for cost-cutting measures will likely increase as profitability and free cash flow remain elusive, according to Amazon.
  • Amazon has seen a 25% drop in its share price in January.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars